Why tomorrow's technology needs a regulatory revolution
200 years ago this month, a 17-year-old Mary Shelley gave birth to a premature daughter, who died at the age of just two weeks. The tragedy was deeply harrowing for Shelley, but it was also a vital part of the history of English literature. Three years later, Shelley published Frankenstein; or, The Modern Prometheus — the book that created not only the indelible title character and his monster, but also the entire genre of science fiction, and the idea that great and wonderful advances in science can have terrible consequences.
Shelley’s idea that modern technology can have a dystopian downside was a powerful one, which never died. Indeed, after two World Wars, one of which was ended by use of the atomic bomb, it became conventional wisdom.
Today, nearly all major technological advances are accompanied by fear. As Douglas Adams put it, “Anything that is in the world when you’re born is normal and ordinary and is just a natural part of the way the world works. Anything that’s invented between when you’re 15 and 35 is new and exciting and revolutionary and you can probably get a career in it. Anything invented after you’re 35 is against the natural order of things.”
Genetically modified food, for instance, is harmless — yet only 37% of US adults consider it safe to eat. And while you might think that many of the big technology successes in recent years have been relatively unthreatening (as Peter Thiel says, “we wanted flying cars; instead we got 140 characters”), that hasn’t stopped Black Mirror from becoming a powerful cultural meme. Now, a much more powerful wave of new technology is fast approaching.
Consider a recent long interview with Demis Hassabis, for instance, the founder of artificial intelligence company DeepMind. Barely has the interview even begun before the journalist brings up the fear that smart computers could mean the end of human life:
The uncertainty lies in whether these artificially intelligent beings will be motivated by a desire to guide and assist us or simply to do away with people like old gadgets that have served their purpose. Also on the YouTube video, Hassabis describes his AI computer playing a boxing game in which, after a few seconds of sparring, it corners the opponent and pummels them into submission. The audience laughs as Hassabis explains that the computer “ruthlessly exploits the weakness in the system it has found”. But perhaps this is an apt analogy. As physicist Stephen Hawking wrote last year, AI would be “the biggest event in human history . . . unfortunately, it might also be the last.”
Hassabis, sensibly, dismisses such concerns out of hand. Other science, however, has managed to frighten even its inventors. Jennifer Doudna, for instance, is at the forefront of one of the most exciting biomedical advances in living memory: engineering the genomes not of plants, but of people. Her cheap and easy Crispr technology holds out the promise that anybody with a gene defect could get that problem fixed, on an individual, bespoke basis. No more one-size-fits all disease cures: everything can now be personalized. The dystopian potential here, of course, is obvious: while Doudna’s name isn’t Frankenstein, you can be sure that if and when her science gains widespread adoption, the parallels will be hammered home ad nauseam.
Doudna is particularly interesting because she doesn’t dismiss fearmongers as anti-science trolls. While she has a certain amount of control over what her own labs do, her scientific breakthrough is in the public domain, now, and already more than 700 papers have been published in the past two years on various aspects of genome engineering. In one high-profile example, a team of researchers found a way of using Doudna’s breakthrough to efficiently and predictably cause lung cancer in mice.
Because Doudna’s technology allows anybody with basic molecular biology training to play around with engineering a human genome, it would be surprising if, somewhere, such experiments didn’t rapidly advance to human experimentation. Or even just scientists experimenting on themselves, given that the cost of sequencing an individual’s genome is now just $1,000.
Meanwhile, at the more mundane end of the technological spectrum, technology companies like Uber and Airbnb have become multi-billion-dollar behemoths in large part through a strategy of aggressive regulatory arbitrage. As venture capitalist Balaji Srinivasan says, one huge reason for Uber’s success is that its founders, faced with orders that it immediately cease operations or face up to 90 days in jail per day that the company kept on operating, made the decision to simply ignore those orders. We all know how that story ended: by flouting the law, not only in San Francisco but in dozens of other cities around the world, Uber’s founders became billionaires.